HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon looks into allegations in China

This article was originally published in The Rose Sheet

Executive Summary

Avon notifies Securities and Exchange Commission and U.S. Department of Justice that it is conducting voluntary internal investigation of its China operations, under the oversight of its Audit Committee, with focus on compliance with Foreign Corrupt Practices Act, according to Oct. 20 release. Investigation launched in June following receipt of allegation that "certain travel, entertainment and other expenses may have been improperly incurred in connection with the company's China operations," firm says. "Investigation is in its early stage, and no conclusion can be drawn at this time as to its outcome," says Avon

You may also be interested in...



Avon Suspends Four Execs As Investigation Goes On Into Bribery Allegations

Avon has suspended four of its executives - three with ties to its operations in China, as well as the company's VP-global finance - in connection with an internal investigation into alleged violations of the U.S. Foreign Corrupt Practices Act

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

UsernamePublicRestriction

Register

RS015739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel